AAV-mediated gene therapy for maple syrup urine disease (MSUD)
AssigneesUniversity of Massachusetts, The Clinic for Special Children, Inc.
InventorsGuangping Gao, Dan Wang, Jiaming Wang, Kevin A. Strauss
Life of this patent
Estimating the term…
Loading patent…
AssigneesUniversity of Massachusetts, The Clinic for Special Children, Inc.
InventorsGuangping Gao, Dan Wang, Jiaming Wang, Kevin A. Strauss
Estimating the term…
In some aspects the disclosure provides compositions and methods for promoting expression of functional BCKDHA protein, which is the E1-alpha subunit of the branched-chain alpha-keto acid (BCAA) dehydrogenase complex, in a subject. In some aspects the disclosure provides compositions and methods for promoting expression of functional BCKDHB protein, which is the E1-beta subunit of the branched-chain alpha-keto acid (BCAA) dehydrogenase complex, in a subject. In some aspects the disclosure provides compositions and methods for promoting expression of functional BCKDHA and BCKDHB proteins, in a subject. In some embodiments, the disclosure provides methods of treating a subject having Maple Syrup Urine Disease (MSUD).
A method for promoting expression of functional BCKDHA protein in a subject, the method comprising administering to the subject an rAAV comprising a capsid containing a nucleic acid engineered to express BCKDHA in the liver and/or skeletal muscle of the subject, wherein the subject comprises at least one BCKDHA allele having a loss-of-function mutation associated with Maple Syrup Urine Disease (MSUD);
Dependencies are inferred from the claim text.